Marley Julia V, Moore Sarah, Fitzclarence Cherelle, Warr Kevin, Atkinson David
The Rural Clinical School of Western Australia, The University of Western Australia, Broome, Western Australia, Australia; Kimberley Aboriginal Medical Services Council, Broome, Western Australia, Australia.
Aust J Rural Health. 2014 Jun;22(3):101-8. doi: 10.1111/ajr.12086.
To compare clinical outcomes and mortality rates between Kimberley Indigenous, other Indigenous and non-Indigenous Australian patients on peritoneal dialysis (PD).
Patients commencing renal replacement therapy (RRT) with PD for the first time from 1 January 2003 to 31 December 2009 were retrospectively identified. Secondary data from medical records and the Australian and New Zealand Dialysis and Transplant Registry from 1 January 2003 to 31 December 2010 were used to compare outcomes between patients.
Time to first peritonitis; failure and death rates per 100 patient-years, hazard ratios, unadjusted and adjusted (for age, sex, comorbid conditions, PD not the first RRT modality used). Comparison of the two PD systems used in the Kimberley.
Kimberley patients had significantly shorter median time to first peritonitis (11.2 versus 21.5 months), higher technique failure (46.0 versus 25.2 per 100 patient-years) and shorter median survival on PD (17.5 versus 22.4 months) but similar adjusted mortality (hazard ratio 1.32; 95% CI, 0.76-2.29) as non-Indigenous patients. They also had a significantly higher technique failure rate than other Indigenous patients (46.0 versus 31.4 per 100 patient-years) and nearly double the average peritonitis episodes previously reported for Indigenous Australians (2.0 versus 1.15 per patient-year).
PD can bring patients closer to home; however, it is relatively short term and potentially hazardous. PD remains an important therapy for suitable remote patients to get closer to home, providing they are fully informed of the options. The current expansion of safer Kimberley haemodialysis options needs to continue.
比较金伯利地区原住民、其他原住民及非原住民澳大利亚腹膜透析(PD)患者的临床结局和死亡率。
回顾性确定2003年1月1日至2009年12月31日首次开始接受PD进行肾脏替代治疗(RRT)的患者。使用2003年1月1日至2010年12月31日医疗记录以及澳大利亚和新西兰透析与移植登记处的二级数据来比较患者之间的结局。
首次发生腹膜炎的时间;每100患者年的失败率和死亡率、风险比、未调整及调整后(针对年龄、性别、合并症、PD并非首次使用的RRT方式)。比较金伯利地区使用的两种PD系统。
金伯利地区患者首次发生腹膜炎的中位时间显著更短(11.2个月对21.5个月),技术失败率更高(每100患者年46.0对25.2),PD治疗的中位生存期更短(17.5个月对22.4个月),但与非原住民患者调整后的死亡率相似(风险比1.32;95%置信区间,0.76 - 2.29)。他们的技术失败率也显著高于其他原住民患者(每100患者年46.0对31.4),且腹膜炎发作平均次数几乎是非原住民澳大利亚人之前报告的两倍(每位患者每年2.0次对1.15次)。
PD可让患者离家更近;然而,它相对短期且有潜在风险。对于合适的偏远地区患者而言,PD仍然是一项重要的治疗方法,可以让他们离家更近,前提是他们充分了解各种选择。目前更安全的金伯利地区血液透析选择的扩展需要继续。